- Conditions
- Hepatocellular Carcinoma
- Interventions
- PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib
- Drug
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • La Jolla, California • Orange, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- PR104, docetaxel, Granulocyte colony-stimulating factor
- Drug
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 25
- States / cities
- San Diego, California • Miami, Florida • Chicago, Illinois + 22 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- PR-104, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- PR-104, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, PR104, F-18-fluoromisonidazole
- Biological · Drug · Other
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Interventions
- PR104
- Drug
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Lung Cancer
- Interventions
- PR104, F-18-fluoromisonidazole
- Drug · Other
- Lead sponsor
- Proacta, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Beverly Hills, California • Greenbrae, California + 13 more